Journal of Current Glaucoma Practice
A Glaucoma Review Journal with DVD

Chief Editors
Tanuj Dada (India), Kuldev Singh (USA), George L Spaeth (USA)

Associate Editors
Yaniv Barkana (Israel), Ronnie George (India), Jovina See (Singapore), Robert J Campbell (Canada)

Managing Editors
Ritu Gadia, Sushmita Kaushik, P Sathyan (India)

Editorial Board

AGP Konstas (Greece)
Ahmed Khalil (Egypt)
Alfonso Antón (Spain)
Alon Harris (USA)
Anders Heijl (Sweden)
Andre Mermoud (Switzerland)
Anil K Mandal (India)
Anja Tuulonen (Finland)
Aung Tin (Singapore)
Balwantray C Chauhan (Canada)
Clive Midgal (UK)
Dan Eisenberg (USA)
David S Friedman (USA)
Dennis Lam (Hong Kong)
Don Minckler (USA)
Felipe Medeiros (USA)
Franz Grehn (Germany)
G Chandrashekhara (India)
G Kumaramanickavel (India)
Ike Ahmed (Canada)
Jonathan G Crowston (Australia)
Joseph Caprioli (USA)
Jost Jonas (Germany)
JP Nordmann (France)
Keith Barton (UK)
Kenji Kashiwagi (Japan)
Linda Zangwill (USA)
Lingam Vijaya (India)
Lutz E Pillunat (Germany)
Makoto Arai (Japan)
Michal Schwartz (Israel)
Mingguang He (China)
Ningli Wang (China)
Paul Chew (Singapore)
Peng T Khaw (UK)
Prin Rojana Pongpun (Thailand)
R Krishnadas (India)
R Ramakrishna (India)
Rajul Parikh (India)
Ramanjit Sihota (India)
Remo Susanna (Brazil)
Robert Stamper (USA)
Roberto G Carassa (Italy)
Shlomo Melamed (Israel)
SS Pandav (India)
Stefano Gandolfi (Italy)
Subhabrat Chakrabarti (India)
Tarek Shaarawy (Switzerland)
William J Feuer (USA)

Senior Editorial Advisors
Erik Greve (Netherland), George Spaeth (USA), Graham Trope (Canada), Ivan Goldberg (Australia), Michael Belkin (Israel), Paul Kaufman (USA), Ravi Thomas (India), Robert Ritch (USA), Robert Weinreb (USA), Roger Hitchings (UK), Sohan S Hayreh (USA), Yoshiaki Kitazawa (Japan)

www.jaypeebrothers.com
Guest Editorial

On Union and Association

I have learned that a prevalent drive in humans is union. An omnipresent powerful and undeniable example is the longing for love; this drive for union however is present in everything from the slightest exchange of words to the United Nations.

Our World Glaucoma Association, Glaucoma Society of India, European Glaucoma Society, American Glaucoma Society and all other associations are based in this drive, the need to convene and communicate, the essence of learning from each other and the wish to help the less advanced. It is, I believe, our human duty and more so our human nature to unite. Of necessity, our world functions also on the basis of multiplicity and contrast. There is a built in (but not spiritual) counterforce to union: disunion or separation (aggression, war, falsehood, sneakiness, blame, distrust, disloyalty, etc.). We experience this counterforce everywhere; it explains the saddest aspects of our human condition. Separation however clearly belongs to the world of manifestation and thus of contrast.

Humans have the choice to live their life either from a consciousness level of original unity (spirit, God, universal intelligence, the uncreated unmanifested, etc.) and express this in the world of form and multitude or to live from a consciousness level of separation, the illusion that is created by contrasting manifestation. The sense of separation is responsible for the apparent difference between me (ego) and the others, the perceived threat that comes from others, the need to defend myself against those threats, and the need to get what I need at all cost whatever the damage.

Operating from a consciousness level of original unity in the world of manifestation comes with the self evident need for union, the absence of fear and the natural desire and will to cooperate. In my view this could be and should be the dominant force in our world even if it may not be immediately obvious. It is the divine truth, the ultimate beauty and the final good. And because of that it will prevail when consciously applied to action. The question is “when”? How close are we to this stage in human development? It has been known for at least 2500 years that individual human beings can reach this state. How long will it take for the majority of humans? Individual human development and development of humanity as a whole are related. So there is hope.

Now, I have no intention of being naïve. We will need top-science, top-diplomacy, top-resources, top-conditions to reach our goals. We need the best individuals and superb leadership. We will not fall into the obvious trap of over-tolerance and pseudo-quality. We will recognize quality differences and will know how to attract and award top-quality.

Having fulfilled these conditions the final result will be based on unity in action, which in turn is based on a personal experience—at the origin of all being of the consciousness level of original unity by the individuals involved. Creation from that origin will be beneficial and effective.

I realize the above may not be the easiest intelligible concept for those who have not had the indubitable experience of union. However, this experience is accessible to all of us with appropriate knowledge and training; and indeed it has shown to be beneficial and effective both in our private and our professional life once experienced.

What is more attractive that applying this approach to our professional organizations?

Erik L Greve
Vice President World Glaucoma Association
With best compliments from

SAPIENT
LABORATORIES PVT. LTD.

AO: 307 L.S.C. DDA MARKET
VIKAS MALL, VIKASPURI
NEW DELHI - 110 018

E-mail: sapient1@rediffmail.com

Put your patient’s eyes
In the most
Refreshing Settings

LUBRIfresh
Sodium carboxy methyl cellulose 0.5% Eye drops

Dry eye syndrome
Computer vision syndrome
Contact lenses
Post-LASIK surgery
Smoke/Dust/Air pollutants

Provide the coolest solution to dry eyes
Contents

Medical Therapy for Glaucoma: The Next 20 Years ................................................................. 1-5
Carol A Rasmussen, Paul L Kaufman

Pathophysiology of Glaucomatous Optic Neuropathy:
Role of Optic Nerve Head Vascular Insufficiency ................................................................. 6-17
Sohan Singh Hayreh

Pseudoexfoliation and Blood Flow Abnormalities ................................................................. 18-25
Rita Ehrlich, Alon Harris, Carlos Rospiglosi López, Nisha S Kheradiya

Detection of Glaucomatous Progression .............................................................................. 26-32
Linda M Zangwill

Glaucoma: The Neuro-ophthalmologic Differential Diagnosis .............................................. 33-38
Mark L Moster, Matthew D Kay

Quality of Life in Glaucoma .................................................................................................. 39-45
Alexander Spratt, Aachal Kotecha, Ananth Viswanathan

To PI or not to PI—That is the Question:
When is a Prophylactic Laser Peripheral Iridotomy Justified? ............................................. 46-49
Yaniv Barkana

Bleb Morphology Assessment and Imaging .......................................................................... 50-55
Mandeep Singh, Paul TK Chew
IN OCULAR HYPERTENSION AND GLAUCOMA

Protect what’s precious

Start with powerful IOP control for lasting patient success.1,4

Xalatan® the world’s leading IOP lowering agent

• 10 years of worldwide and Indian clinical experience
• More than 99 million prescriptions worldwide
• Over 400 peer reviewed publications

In clinical trials with XALATAN®, the most common ocular adverse effects included eye irritation, conjunctival hyperaemia, transient punctate epithelial erosions, increased iris pigmentation, and eye pain.¹


SUMMARY OF PRESCRIBING INFORMATION FOR XALATAN

Composition: Bottles containing 2.5 ml ophthalmic solution, 1 ml contains 50 mcg of latanoprost. One drop contains approximately 1.5 mcg of latanoprost. Indications: Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma, chronic angle closure glaucoma, and ocular hypertension. Contraindications: Known hypersensitivity to latanoprost or any other component of the product. Adverse Reactions: Reported as part of clinical development or post marketing surveillance were: Eye irritation (burning, grittiness, itching, stinging and foreign body sensation), blepharitis, conjunctival hyperaemia, eye pain, increased pigmentation of the iris, transient punctate epithelial erosions, and eyelid edema, corneal edema and erosions; conjunctivitis; eyelash and vellus hair changes, iritis, keratitis, macular edema, misdirected eyelashes, blurred vision, darkening of the palpebral skin and localized skin reaction on the eyelids. Other adverse reactions include skin rash, dizziness, headache, asthma and aggravation, acute asthma attacks, dyspnea, muscle/joint pain and non-specific chest pain. Warnings and Precautions: May cause increased brown pigmentation of iris, reversible eye lid skin darkening. May gradually change eyelashes and vellus hair in the treated eye. Heterochromia, and macular edema, including cystoid macular edema, especially in aphakic, pseudophakic patients with torn posterior lens capsule, or those with known risk factors for macular edema. Limited experience in the treatment of inflammatory neovascular or congenital glaucoma. No adequate and well-controlled studies in pregnant women, used with caution in nursing women. Patients should not drive or use machines while on Xalatan®.

Dosage: One drop in the affected eye(s) once daily. Optimal effect obtained if administered in the evening. Dose should not exceed once daily. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart. Safety and effectiveness not established in children.

DVD Contents

SCANDINAVIAN HEIDELBERG GLAUCOMA SYMPOSIUM

The Role of Imaging in Diagnosing Glaucoma (Albert Alm, Sweden)
Qualitative and Quantitative Analysis of the Baseline Examination (Reinhard Burk, Germany)
Benefits of Early Detection in Angle-closure Glaucoma (Paul Foster)
Structure and Function in Glaucoma (Albert Alm, Sweden)
Monitoring and Interpreting Progression (Ted Garway-Heath, UK)
Monitoring Outcomes of Treatment in Angle-closure (Paul Foster, UK)

IMPLANTATION OF AHMED GLAUCOMA SHUNT WITH PARS PLANA SCLEROTOMY FOR NEOVASCULAR GLAUCOMA (Karanjit S Kooner, USA)

PHACO-COMBINED WITH AGV (Uday Devgan, USA)

PHACOEMULSIFICATION WITH FIXATION OF THE CAPSULAR BAG IN PSEUDOEXFOLIATION SYNDROME (Ike Ahmed, Canada)

TECHNIQUE FOR SELECTIVE LASER TRABECULOPLASTY (Madhu Nagar, UK)

System requirement:
• Windows XP or above
• Power DVD player (Software)
• Windows media player version 10.0 or above
• Quick time player version 6.5 or above

Accompanying DVD ROM is playable only in Computer and not in DVD player.
Kindly wait for few seconds for DVD to autorun. If it does not autorun then please do the following:
• Click on my computer
• Click the drive labelled JAYPEE and after opening the drive, kindly double click the file Jaypee